Navigation Links
Novel EGFR ectodomain mutations in glioblastoma

The Epidermal Growth Factor Receptor (EGFR), a so-called kinase protein, is often abnormally active in cancer. A new class of anticancer drugs inhibiting the activated EGFR kinase have shown to be effective against such cancers, especially lung cancer. In a new study in PLoS Medicine, researchers have catalogued and characterized the mutations in the EGFR gene that occur in glioblastoma, a deadly type of brain tumor. The researchers sequenced the whole coding sequence of the EGFR gene in more than 100 glioblastomas. Nearly 15% of the tumors contained missense mutations—changes that altered the amino acid sequence of EGFR.

But the mutations were mostly different from the ones commonly seen in other cancers: rather than changing the kinase domain, most of the gliobastoma-associated mutations mapped to the extracellular domain of the protein. These findings identify missense mutations in the extracellular domain of EGFR as a new way to oncogenically activate this protein. Fortunately, the drugs developed to inhibit EGFR have broad activity, which bodes well for the use of these drugs in patients with glioblastoma.
'"/>

Source:Public Library of Science


Page: 1

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. Discovery Could Lead To Novel Approaches In HIV Treatment
7. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
8. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
9. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
10. Novel live reporting system to track cells
11. Field of beams - Novel system uses polarized light pulses to reveal crop health
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... ... August 16, 2017 , ... ... Food and Drug Administration (FDA) inspection at our Dilworth, MN site. The inspection ... issued. This inspection was conducted as part of a routine Bioresearch Monitoring Program ...
(Date:8/15/2017)... After spending the past two years building a state-of-the-art technology which ... offers this platform to healthcare stakeholders (hospitals, foundations, biopharma companies etc.) ... collection vis a vis their members, under their own brand. Three ... offer. ... ...
(Date:8/15/2017)... ... August 15, 2017 , ... Pittcon is ... for analytical and scientific instruments. This year’s symposium, organized by the Pittcon 2018 ... Spectrometry for Bioanalytical Applications.” This dynamic presentation will discuss novel ionization processes, high ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum ... 360° (IO360°) programming through a series of upcoming panels and events. The partnership culminates ... at The Roosevelt Hotel in New York City. , “With our experience in producing ...
Breaking Biology Technology: